单细胞测序在血液肿瘤疾病中的应用进展

Application progress of single cell sequencing in blood tumor diseases

单细胞测序(single cell sequencing,SCS)技术指在单个细胞水平上,对基因组或转录组进行扩增并测序的技术,较传统测序方法具有发现细胞异质性及使用生物材料较少等优势。近年来,随着测序成本逐渐降低,SCS技术在科研中越来越受到关注,特别是在血液肿瘤疾病诊治方面。血液肿瘤疾病具有高度异质性,而SCS技术有助于揭示其发病及克隆演变机制。本文就近几年SCS技术在血液肿瘤疾病中的应用进展作一综述,旨在为血液肿瘤疾病的诊断与靶向治疗提供临床指导。

Single cell sequencing(SCS) refers to the amplification and sequencing of genome or transcriptome at the level of single cell.Compared with traditional sequencing methods,SCS has the advantages of discovering the heterogeneity between cells and using less biomaterials.In recent years,with the cost of sequencing gradually reduced,SCS has attracted more and more attention in scientific research,especially in the diagnosis and treatment of blood tumor diseases.Blood tumor diseases are highly heterogeneous,and SCS is helpful to reveal the pathogenesis and clonal evolution mechanism.This paper reviewed the application of SCS in hematological tumor diseases in recent years,aiming to provide clinical guidance for the diagnosis and targeted therapy of hematological tumor diseases.